This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
(April 2019) (Learn how and when to remove this template message)
|Trade names||Lafamme, Natazia, Qlaira|
|Other names||EV/DNG; SH T00658ID; Bay 86-5027; BAY86-5027|
|AHFS/Drugs.com||Professional Drug Facts|
|Drug class||Estrogen; Progestogen|
Estradiol valerate/dienogest (EV/DNG), sold under the brand names Lafamme, Natazia and Qlaira among others, is a combination product of estradiol valerate, an estrogen, and dienogest, a progestogen, which is used in menopausal hormone therapy in and as a birth control pill to prevent pregnancy in women. It is taken by mouth.
Birth control pills containing EV/DNG are associated with a significantly increased risk of venous thromboembolism. However, they are associated with a significantly lower risk of venous thromboembolism than birth control pills containing ethinylestradiol and a progestin.
- Estradiol valerate/cyproterone acetate
- Estradiol/nomegestrol acetate
- List of combined sex-hormonal preparations
- "Dienogest / estradiol (Natazia) Use During Pregnancy". Drugs.com. 27 January 2020. Retrieved 18 March 2020.
- Fruzzetti F, Cagnacci A (2018). "Venous thrombosis and hormonal contraception: what's new with estradiol-based hormonal contraceptives?". Open Access J Contracept. 9: 75–79. doi:10.2147/OAJC.S179673. PMC 6239102. PMID 30519125.
- "Dienogest mixture with Estradiol valerate". Drug Information Portal. U.S. National Library of Medicine.